Akari Therapeutics PLC (AKTX) - Total Assets
Based on the latest financial reports, Akari Therapeutics PLC (AKTX) holds total assets worth $45.38 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See net assets of Akari Therapeutics PLC for net asset value and shareholders' equity analysis.
Akari Therapeutics PLC - Total Assets Trend (2010–2024)
This chart illustrates how Akari Therapeutics PLC's total assets have evolved over time, based on quarterly financial data.
Akari Therapeutics PLC - Asset Composition Analysis
Current Asset Composition (December 2024)
Akari Therapeutics PLC's total assets of $45.38 Million consist of 5.8% current assets and 94.2% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 5.1% |
| Accounts Receivable | $201.00K | 0.4% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $39.18 Million | 77.5% |
| Goodwill | $8.43 Million | 16.7% |
Asset Composition Trend (2010–2024)
This chart illustrates how Akari Therapeutics PLC's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Akari Therapeutics PLC stock valuation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Akari Therapeutics PLC's current assets represent 5.8% of total assets in 2024, a decrease from 100.0% in 2010.
- Cash Position: Cash and equivalents constituted 5.1% of total assets in 2024, up from 0.0% in 2010.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 93.0% of total assets, an increase from 0.0% in 2010.
- Asset Diversification: The largest asset category is intangible assets at 77.5% of total assets.
Akari Therapeutics PLC Competitors by Total Assets
Key competitors of Akari Therapeutics PLC based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO
|
USA | $185.55 Million |
|
Summit Therapeutics PLC
NASDAQ:SMMT
|
USA | $261.73 Million |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS
|
USA | $1.08 Billion |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
BrightGene Bio Medical Technology C
SHG:688166
|
China | CN¥5.38 Billion |
|
BioArctic AB (publ)
ST:BIOA-B
|
Sweden | Skr2.60 Billion |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
Akari Therapeutics PLC - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.19 | 0.29 | 2.79 |
| Quick Ratio | 0.19 | 0.29 | 2.79 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-12.62 Million | $-6.69 Million | $9.36 Million |
Akari Therapeutics PLC - Advanced Valuation Insights
This section examines the relationship between Akari Therapeutics PLC's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.39 |
| Latest Market Cap to Assets Ratio | 0.34 |
| Asset Growth Rate (YoY) | 1061.0% |
| Total Assets | $50.56 Million |
| Market Capitalization | $16.96 Million USD |
Valuation Analysis
Below Book Valuation: The market values Akari Therapeutics PLC's assets below their book value (0.34x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Akari Therapeutics PLC's assets grew by 1061.0% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Akari Therapeutics PLC (2010–2024)
The table below shows the annual total assets of Akari Therapeutics PLC from 2010 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $50.56 Million | +1061.01% |
| 2023-12-31 | $4.36 Million | -68.52% |
| 2022-12-31 | $13.83 Million | +18.75% |
| 2021-12-31 | $11.65 Million | -20.25% |
| 2020-12-31 | $14.60 Million | +41.70% |
| 2019-12-31 | $10.31 Million | -37.35% |
| 2018-12-31 | $16.45 Million | -43.37% |
| 2017-12-31 | $29.05 Million | -36.67% |
| 2016-12-31 | $45.87 Million | -34.37% |
| 2015-12-31 | $69.89 Million | +978.60% |
| 2014-12-31 | $6.48 Million | -17.26% |
| 2013-12-31 | $7.83 Million | +599.29% |
| 2012-12-31 | $1.12 Million | +4048.15% |
| 2011-12-31 | $27.00K | -21.55% |
| 2010-12-31 | $34.42K | -- |
About Akari Therapeutics PLC
Akari Therapeutics, Plc, an oncology company, develops next-generation antibody-drug conjugates (ADC) for cancer-killing toxins. Its lead payload is PH1 to disrupt the function of spliceosomes and to trigger an immune response that leads to additional cancer cell killing. The company's lead product candidate is AKTX-101, a preclinical stage trop2-targeting ADC that combines PH1 with the trop2 ant… Read more